Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors.

Trial Profile

Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2017

At a glance

  • Drugs BNC 105 (Primary) ; Everolimus
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DisrupTOR-1
  • Most Recent Events

    • 17 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 14 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016.
    • 14 Nov 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Nov 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top